Although TNF-α inhibitors and other RA biologics are generally considered efficacious and safe and adequately control disease in many conventional DMARD-refractory RA patients, therapies that are more effective in reducing the signs and symptoms of RA and that can sustain efficacy over time are needed. Novel agents able to demonstrate strong efficacy in these attributes will have substantial influence on physicians’ prescribing decisions for RA. We provide quantitative insight into U.S. and European rheumatologists’ perceptions of key treatment drivers and goals and the current level of unmet need in this indication. We analyze the commercial opportunities in the treatment of RA and discuss how emerging therapies can capitalize on these opportunities. Additionally, using an adaptive choice-based conjoint analysis, we offer an assessment of trade-offs, across clinical attributes and price, that can impact physicians’ prescribing likelihood and preference share of select target product profiles.

Questions Answered:

  • What are the treatment drivers and goals for RA?
  • What attributes are key influences, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals for RA?
  • What are the prevailing areas of unmet need and opportunity in RA?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European rheumatologists for a hypothetical new RA drug?

Markets covered: United States, France, Germany, United Kingdom

Primary research: Survey of 60 U.S. and 31 European rheumatologists fielded in December 2016.

Key companies: AbbVie, Biogen Idec, Bristol-Myers Squibb, Eli Lilly, Incyte, Janssen, Pfizer, Roche

Key drugs: Humira, Remicade, Rituxan/MabThera, Orencia, Actemra/RoActemra, Xeljanz, baricitinib

Table of contents

  • Rheumatoid Arthritis - Unmet Need - Detailed, Expanded Analysis (US/EU)
    • Treatment Drivers and Goals
      • Overview
      • Rationale for Treatment Drivers and Goals Selection
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
        • Nonclinical Factors
      • Physician Rating of Treatment Drivers and Goals in Rheumatoid Arthritis
        • Importance of Efficacy Attributes to Prescribing Decisions in Rheumatoid Arthritis: United States
        • Importance of Efficacy Attributes to Prescribing Decisions in Rheumatoid Arthritis: Europe
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in Rheumatoid Arthritis: United States
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in Rheumatoid Arthritis: Europe
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in Rheumatoid Arthritis: United States
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in Rheumatoid Arthritis: Europe
        • Importance of Nonclinical Factors to Prescribing Decisions in Rheumatoid Arthritis: United States
        • Importance of Nonclinical Factors to Prescribing Decisions in Rheumatoid Arthritis: Europe
      • Stated vs. Derived Importance of Treatment Drivers and Goals
        • Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Rheumatoid Arthritis: United States
        • Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Rheumatoid Arthritis: Europe
    • Product Performance Against Treatment Drivers and Goals
      • Overview
      • Rationale for Drug Selection
        • Products for Rheumatoid Arthritis
      • Current Brand Performance on Key Treatment Drivers and Goals
        • Overall Performance of Key Therapies for Rheumatoid Arthritis: United States
        • Overall Performance of Key Therapies for Rheumatoid Arthritis: Europe
        • Relative Performance of Key Therapies for Rheumatoid Arthritis Across Select Efficacy Attributes: United States
        • Relative Performance of Key Therapies for Rheumatoid Arthritis Across Select Efficacy Attributes: Europe
        • Relative Performance of Key Therapies for Rheumatoid Arthritis Across Select Safety and Tolerability Attributes: United States
        • Relative Performance of Key Therapies for Rheumatoid Arthritis Across Select Safety and Tolerability Attributes: Europe
        • Relative Performance of Key Therapies for Rheumatoid Arthritis Across Select Convenience of Administration Attributes: United States
        • Relative Performance of Key Therapies for Rheumatoid Arthritis Across Select Convenience of Administration Attributes: Europe
        • Relative Performance of Key Therapies for Rheumatoid Arthritis Across Select Nonclinical Attributes: United States
        • Relative Performance of Key Therapies for Rheumatoid Arthritis Across Select Nonclinical Attributes: Europe
    • Assessment of Unmet Need
      • Overview
      • Overall Satisfaction with Current Treatment
        • Surveyed Rheumatologists’ Satisfaction with the Performance of Key Therapies for Rheumatoid Arthritis on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: United States
        • Surveyed Rheumatologists’ Satisfaction with the Performance of Key Therapies for Rheumatoid Arthritis on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: Europe
      • Physician Rating of Unmet Need in Rheumatoid Arthritis
        • Surveyed Rheumatologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Rheumatoid Arthritis: United States
        • Surveyed Rheumatologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Rheumatoid Arthritis: Europe
        • Surveyed Rheumatologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Rheumatoid Arthritis: United States
        • Surveyed Rheumatologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Rheumatoid Arthritis: Europe
        • Surveyed Rheumatologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Rheumatoid Arthritis: United States
        • Surveyed Rheumatologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Rheumatoid Arthritis: Europe
        • Surveyed Rheumatologists' Ascribed Level of Unmet Need Across Key Nonclinical Factors in Rheumatoid Arthritis: United States
        • Surveyed Rheumatologists' Ascribed Level of Unmet Need Across Key Nonclinical Factors in Rheumatoid Arthritis: Europe
      • Unmet Need in Rheumatoid Arthritis and Related Indications
        • Surveyed Rheumatologists' Ascribed Level of Unmet Need in Rheumatoid Arthritis and Related Indications: United States
        • Surveyed Rheumatologists' Ascribed Level of Unmet Need in Rheumatoid Arthritis and Related Indications: Europe
    • Opportunity Analysis
      • Areas of Opportunity in the Rheumatoid Arthritis Market and Emerging Therapy Insights
        • Opportunity: A Novel Agent Demonstrating Improved Efficacy in Reducing Signs and Symptoms of Disease and Inducing Clinical Remission
        • Opportunity: A Novel Agent with a Lower Risk of Serious Adverse Events
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
        • Attributes and Attribute Levels
      • Attribute Importance and Part-Worth Utilities
        • Rheumatoid Arthritis Target Product Profile: Attribute Importance
        • ACR 50 Response in DMARD-Refractory Patients at Three Months (% of Patients)
        • Remission (DAS28 < 2.6) in DMARD-Refractory Patients at Six Months (% of Patients)
        • Maintained ACR 50 Response in DMARD-Refractory Patients at Two Years (% of Patients)
        • Rate of Serious Infections (per 100 Patient-Years)
        • Length of Postmarketing Safety Surveillance (Time on Market)
        • Route and Frequency of Administration
        • Price per Day (Relative to Humira)
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Rheumatoid Arthritis Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 1
        • Rheumatoid Arthritis Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 1
        • Rheumatoid Arthritis Market Simulations: Target Product Profiles Included in Scenario 1
        • Rheumatoid Arthritis Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 2
        • Rheumatoid Arthritis Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 2
        • Rheumatoid Arthritis Market Simulations: Target Product Profiles Included in Scenario 2
    • Appendix
      • Key Abbreviations
      • Experts Interviewed
      • Bibliography

Author(s): Emily Schriner, MPH

Emily is an Business Insights Analyst with the Immune and Inflammatory Disorders team at Decision Resources Group. She has authored several content pieces for immune market research reports and keeps the team up-to-date on the immune markets through research on patent life, pricing, and pipeline information.

Emily earned her Master of Public Health in Nutrition at West Chester University, focusing on research, analysis, and program development. She completed an internship at Nemours Health Network in Wilmington, Delaware where she did nutrition education development and primary research on program evaluation before initially joining DRG as a data analyst on the Research Analytics Team.


Related Reports

Rheumatoid Arthritis - Landscape & Forecast - Disease Landscape & Forecast

The increasingly crowded RA market boasts many targeted agents representing several different drug classes, including blockbuster

View Details

Rheumatoid Arthritis | Disease Landscape and Forecast | G7 | 2020

The increasingly crowded RA market boasts many targeted agents representing several different drug classes, including blockbuster TNF-α inhibitors, five non-TNF-α biologics (including the second IL...

View Details

Rheumatoid Arthritis - Current Treatment - Rheumatoid Arthritis | Treatment Algorithms: Claims Data Analysis | US | Dashboard

MARKET OUTLOOK Rheumatoid arthritis (RA) is characterized by chronic and progressive joint inflammation that commonly leads to permanent, debilitating tissue damage and cartilage and bone d...

View Details

Rheumatoid Arthritis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

MARKET OUTLOOKRheumatoid arthritis (RA) is characterized by chronic and progressive joint inflammation that commonly leads to permanent, debilitating tissue damage and cartilage and bone des...

View Details